ABSTRACT
OBJECTIVE: This study assessed flow-mediated vasodilation (FMD) and brachial artery diameter (BAD) in HIV-infected pregnant women compared to healthy pregnant controls, and determined their relationships to variables of interest, including the HIV status. METHODS: Subjects were enrolled prospectively for this longitudinal, observational study. Body mass index (BMI), blood pressure (BP), fasting lipoprotein profiles, homeostasis model assessment of insulin resistance (HOMA-IR), FMD, and BAD were assessed at 10-12, 20-22, and 32-35weeks gestation in HIV-infected women and healthy controls aged 18-45years with singleton pregnancies. RESULTS: Fourteen HIV-infected women and 19 controls were enrolled. Groups were similar at baseline except there were more Caucasians in the control group (P<0.01). FMD and BAD did not change during pregnancy in either group, and there were no differences between groups. In multivariable regression analysis, FMD was associated with BAD (P=0.002), but not with age, BMI, BP, TC, TG, HOMA-IR, or HIV status. No variables were associated with BAD. CONCLUSION: No differences were observed in FMD or BAD between HIV-infected and healthy pregnant women, and neither measure changed significantly during pregnancy. HIV status did not affect endothelial function or brachial artery diameter. Pregnancy does not appear to further increase the CVD risk associated with HIV infection.
ABSTRACT
OBJECTIVES: Studies regarding the effects of parity on blood pressure in later life produced conflicting results. The aim of our study is to analyse whether parity influences the prevalence of hypertension in perimenopausal and postmenopausal women. METHODS: One thousand perimenopausal and postmenopausal women (mean age 55.2â±â5.4 years) were enrolled with a median follow-up of 63.0 months. The study sample consisted of patients who self-referred, in 1998-2009, to the BenEssere Donna Clinic, dedicated to menopause-related disorders. RESULTS: One hundred and twenty-two (12.2%) women were nulliparous and 878 (87.8%) had at least one child. Thirty-four (27.9%) women among nulliparous and 326 (37.1%) among parous were hypertensive at baseline (Pâ=â0.046) and 812 women (81.2%) were in their postmenopausal period. Univariate analysis showed that women with one or more children were at higher risk of being hypertensive [odds ratio (OR): 1.529; 95% confidence interval (CI): 1.006-2.324; Pâ=â0.047]. Likewise, multivariate analysis revealed that parity (OR: 2.907; 95% CI: 1.290-6.547; Pâ=â0.010), BMI (OR: 1.097; 95% CI: 1.048-1.149; Pâ<â0.001) and family history of hypertension (OR: 3.623; 95% CI: 2.231-5.883; Pâ<â0.001) were independently related to hypertension at baseline. In a subanalysis of 640 initially normotensive women, 109 (17.0%) patients developed hypertension after follow-up, without a statistically significant association with parity (13.6% in nulliparous versus 17.6% in parous; Pâ=â0.362). Consistently, parity showed no relationship with the incidence of hypertension during follow-up (OR: 1.350; 95% CI: 0.707-2.579; Pâ=â0.363). CONCLUSION: For the first time in a population of White perimenopausal and postmenopausal women, parity was demonstrated to be independently associated with early hypertension during menopausal transition. Conversely, postmenopausal hypertension was not related with parity.
Subject(s)
Hypertension/physiopathology , Menopause , Parity , Female , Humans , Middle Aged , Pregnancy , Prospective Studies , Retrospective StudiesABSTRACT
Primary percutaneous coronary intervention (PCI) encompassing stent implantation is a mainstay in the management of acute ST-elevation myocardial infarction (STEMI). Despite refinements in techniques and devices, peri- and post-procedural antithrombotic therapy remains pivotal to prevent early and late thrombotic events, without unduly increasing bleeding risk. Concomitant dual antiplatelet therapy with aspirin and clopidogrel has been considered until recently the standard of care in terms of oral antiplatelet agents. However, most recently a novel and more potent thienopyridine, prasugrel, has been tested in randomized trials including patients with STEMI, and subsequently approved for clinical practice in Europe and North America. Despite its potent antithrombotic effect, prasugrel also carries a statistically significant increase in the risk of bleeding, especially in the elderly, those with low body weight, and previous stroke or transient ischemic attack. Thus, the use of prasugrel, as well as that of clopidogrel or ticagrelor, should best be individualized to maximize clinical benefits and minimize hazards.
Subject(s)
Angioplasty, Balloon, Coronary , Arrhythmias, Cardiac/drug therapy , Evidence-Based Medicine , Myocardial Infarction/drug therapy , Piperazines/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Thiophenes/therapeutic use , Thrombosis/prevention & control , Angioplasty, Balloon, Coronary/adverse effects , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/surgery , Combined Modality Therapy , Hemorrhage/chemically induced , Hemorrhage/prevention & control , Humans , Myocardial Infarction/physiopathology , Myocardial Infarction/surgery , Piperazines/adverse effects , Platelet Aggregation Inhibitors/adverse effects , Prasugrel Hydrochloride , Precision Medicine , Purinergic P2Y Receptor Antagonists/adverse effects , Purinergic P2Y Receptor Antagonists/therapeutic use , Stents/adverse effects , Thiophenes/adverse effects , Thrombosis/etiologyABSTRACT
BACKGROUND: Left atrium (LA) enlargement is common in organic mitral regurgitation (MR) and is an emerging prognostic indicator. However, outcome implications of LA enlargement have not been analyzed in the context of routine clinical practice and in a multicenter study. METHODS AND RESULTS: The Mitral Regurgitation International DAtabase (MIDA) registry enrolls patients with organic MR due to flail leaflets, diagnosed in routine clinical practice, in 5 US and European centers. We investigated the relation between LA diameter and mortality under medical treatment and after mitral surgery in 788 patients in sinus rhythm (64±12 years; median LA, 48 [43 to 52] mm). LA diameter was independently associated with survival after diagnosis (hazard ratio, 1.08 [1.04 to 1.12] per 1 mm increment). Compared with patients with LA <55 mm, those with LA ≥55 mm had lower 8-year overall survival (P<0.001). LA ≥55 mm independently predicted overall mortality (hazard ratio, 3.67 [1.95 to 6.88]) and cardiac mortality (hazard ratio, 3.74 [1.72 to 8.13]) under medical treatment. The association of LA ≥55 mm and mortality was consistent in subgroups. Similar excess mortality associated with LA ≥55 mm was observed in asymptomatic and symptomatic patients (P for interaction, 0.77). In patients who underwent mitral surgery, LA ≥55 mm had no impact on postoperative outcome (P>0.20). Mitral surgery was associated with greater survival benefit in patients with LA ≥55 mm compared with LA <55 mm (P for interaction, 0.008). CONCLUSIONS: In MR caused by flail leaflets, LA diameter ≥55 mm is associated with increased mortality under medical treatment, independent of the presence of symptoms or left ventricular dysfunction.
Subject(s)
Atrial Function, Left/physiology , Echocardiography, Doppler/methods , Heart Atria/diagnostic imaging , Mitral Valve Insufficiency/mortality , Mitral Valve/diagnostic imaging , Aged , Cause of Death/trends , Disease Progression , Europe/epidemiology , Female , Follow-Up Studies , Heart Atria/physiopathology , Humans , Male , Middle Aged , Mitral Valve Insufficiency/diagnostic imaging , Mitral Valve Insufficiency/physiopathology , Prognosis , Retrospective Studies , Risk Factors , Severity of Illness Index , Survival Rate/trends , United States/epidemiologyABSTRACT
BACKGROUND: Epicardial adipose tissue (EAT) is increased in HIV-infected patients. The aim of this study was to evaluate the association between EAT and coronary artery calcium (CAC) a marker of atherosclerosis; furthermore, we investigated the association of EAT with HIV infection, antiretroviral therapy (ART), and lipodystrophy. METHODS: This was a cross-sectional study of 876 consecutive HIV-infected ART experienced patients. Patients underwent CAC imaging with multidetector computed tomography (CT) for atherosclerosis screening and risk of cardiovascular events (CAC score >100); EAT was measured in the same CT images. Factors independently associated with EAT were explored in a multivariable backward stepwise linear regression analysis. Multivariable logistic regression was used to evaluate the association of EAT and CAC score greater than 100. RESULTS: Patients' mean age was 47.2 ± 8 years, 68% were men. EAT was associated with central fat accumulation and mixed lipodystrophy phenotypes. Factors independently associated with EAT were: age [ß = 0.6, confidence interval (CI) 0.2-1.0], male sex (ß = 6.6, CI 0.5-12.7), visceral adipose tissue (ß = 0.12, CI 0.08-0.17), waist circumference (ß = 0.7, CI 0.04-1.3), current CD4⺠(ß = 0.6, CI 0.1-1.2, per 50 cells), total cholesterol (ß = 0.1, CI 0.02-0.15), and cumulative exposure to ART (months) (ß = 0.05, CI 0.00-0.11). EAT (per 10 cm³) was associated with CAC greater than 100 (odds ratio = 1.10, CI 1.02-1.19) after adjustment for age, male sex, and diabetes. CONCLUSION: We showed an association between EAT and central fat accumulation and mixed form lipodystrophy phenotypes as well as traditional risk factors for atherosclerosis. EAT may be a useful marker of cardiovascular risk as shown by its association with CAC greater than 100.
Subject(s)
Adipose Tissue/pathology , Cardiovascular Diseases/complications , HIV Infections/drug therapy , HIV-Associated Lipodystrophy Syndrome/complications , Pericardium/pathology , Adipose Tissue/diagnostic imaging , Adipose Tissue/virology , Anti-Retroviral Agents/therapeutic use , Biomarkers/analysis , Calcium/analysis , Coronary Artery Disease/complications , Cross-Sectional Studies , Female , HIV Infections/diagnostic imaging , HIV Infections/virology , HIV-Associated Lipodystrophy Syndrome/diagnostic imaging , HIV-Associated Lipodystrophy Syndrome/virology , Humans , Male , Middle Aged , Risk Factors , Tomography, X-Ray ComputedABSTRACT
OBJECTIVES: Endothelial dysfunction is known to be associated with atherosclerosis progression and cardiovascular events. Limited information exists regarding the importance of this topic in hypertensive postmenopausal women. In this particular population the influence of endothelial dysfunction on cardio-vascular end cerebro-vascular events is well demonstrated. Therefore, we investigated, in a prospective study, the influence of endothelial-dependent vasodilation on carotid intima-media thickness (IMT) progression in our population of hypertensive postmenopausal women. METHODS: In addition to common risk factors and pharmacological therapy, we measured carotid IMT and flow-mediated dilation (FMD) of the brachial artery at baseline and after 1 year of follow-up. RESULTS: Baseline and follow-up data were available for 618 hypertensive postmenopausal women with an age of 55 ± 8 years. The mean IMT at baseline was 754 ± 161 µm [interquartile range (IQR) from 600 to 838 µm]. The mean FMD at baseline was 5.8 ± 3.9% (IQR from 3.2 to 8.2%). There was a significant correlation between baseline FMD and carotid IMT (r = -0.16; P = 0.003). Mean IMT progression resulted in 103 µm (range from -250 to 567 µm; IQR from 0 to 200 µm) per year. Baseline FMD, FMD change and the amount of SBP reduction during follow-up remained the independent predictors of IMT progression in multivariable analysis. CONCLUSIONS: In this prospective study we observed a significant interaction between baseline FMD, FMD change during follow-up and IMT progression in our population of hypertensive postmenopausal women. These results are in accordance with the suggestion that endothelial dysfunction is associated with enhanced atherosclerosis development. This hypothesis could provide a pathophysiological explanation for the increase in cardio-vascular and cerebro-vascular episodes recorded in hypertensive postmenopausal women with endothelial dysfunction.
Subject(s)
Atherosclerosis/physiopathology , Carotid Arteries/pathology , Endothelium, Vascular/physiopathology , Hypertension/physiopathology , Antihypertensive Agents/therapeutic use , Atherosclerosis/complications , Disease Progression , Female , Humans , Hypertension/complications , Hypertension/drug therapy , Middle Aged , Prospective StudiesABSTRACT
BACKGROUND: Despite the increasing use of transradial techniques for cardiac percutaneous procedures, none of the strategies commonly utilized for hemostasis has been able to reduce the occurrence of radial artery occlusion (RAO). The aim of this study was to evaluate the occurrence of 24-hour RAO and the rate of bleeding of a novel hemostatic device for radial closure after percutaneous interventions, in adjunct to short-time compression. METHODS: Once the radial access was obtained, patients were randomized to 3 different strategies of radial closure: a short compression with the QuikClot® Interventional™ pad (Z-Medica Corporation, Wallingford, CT, USA) (15 minutes, group 1), a short compression (15 minutes, group 2), and a conventional prolonged compression (2 hours, group 3) both without QuikClot® utilization. RESULTS: Fifty patients in group 1, 20 in group 2, and 50 in group 3 were enrolled. The three groups were homogenous for baseline and procedural characteristics. None of patients in group 1 developed RAO, 1 (5%) occurred in group 2, and 5 (10%) in group 3 (P = 0.05). Active bleeding after compression removal occurred in 10 patients (20%) in group 1, 18 (90%) in group 2, and 1 (2%) in group 3 (P < 0.001). Among patients in group 1, at univariate analysis, the predictors of acute bleeding resulted in chronic therapy with clopidogrel (Odds Ratio 28.78, 95% Confidence Intervals 4.79-172.82, P < 0.001) and high levels of activated clotting time (ACT) at the time of sheath removal (OR 1.02, 95% CI 1.00-1.03, P = 0.009). At ROC analysis, the cutoff value of ACT for the risk of bleeding with a sensitivity of 80% and specificity of 75% was 287 seconds. CONCLUSIONS: Early sheet removal and short-time compression with QuikClot® Interventional™ can reduce the rate of RAO after diagnostic or interventional procedures especially in patients not on double antiplatelet therapy.
Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Arterial Occlusive Diseases/prevention & control , Hemorrhage/prevention & control , Hemostatic Techniques/instrumentation , Kaolin/therapeutic use , Radial Artery/pathology , Angioplasty, Balloon, Coronary/methods , Antidiarrheals/therapeutic use , Blood Coagulation Tests , Confidence Intervals , Female , Hemorrhage/etiology , Humans , International Normalized Ratio , Male , Middle Aged , Odds Ratio , Pressure , Radial Artery/injuries , Risk Factors , Sensitivity and Specificity , Time Factors , Vascular PatencyABSTRACT
Double-arterial coronary stent thrombosis in acute myocardial infarction (AMI) is an infrequent but severe complication, especially when the third main coronary artery is chronically occluded. The conus artery (CA) can serve as a major source of collateral when the left anterior descendent coronary artery (LAD) becomes obstructed. We report a case of a 48-year-old man presenting with AMI due to a very late double-arterial stent thrombosis (ST) following drug-eluting stent implantation and a chronic occlusion of LAD collateralized by a large anomalous CA, which provided for the entire vascularization of the coronary tree.
Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Coronary Occlusion/complications , Coronary Vessel Anomalies/complications , Myocardial Infarction/etiology , Thrombosis/etiology , Angioplasty, Balloon, Coronary/instrumentation , Chronic Disease , Collateral Circulation , Coronary Circulation , Coronary Occlusion/physiopathology , Coronary Occlusion/therapy , Coronary Vessel Anomalies/physiopathology , Coronary Vessel Anomalies/therapy , Drug-Eluting Stents , Fibrinolytic Agents/therapeutic use , Humans , Male , Metals , Middle Aged , Myocardial Infarction/physiopathology , Myocardial Infarction/therapy , Platelet Aggregation Inhibitors/therapeutic use , Prosthesis Design , Stents , Thrombosis/physiopathology , Treatment OutcomeABSTRACT
BACKGROUND: The Mehran Risk Score (MRS) has been demonstrated to be clinically useful for prediction of contrast-induced nephropathy (CIN) after nonurgent percutaneous coronary intervention. We aim to validate the MRS in the setting of Primary percutaneous coronary intervention for prediction of both CIN and short- and long-term clinical outcomes. METHODS AND RESULTS: We assigned 891 consecutive patients with ST-elevation-myocardial infarction undergoing primary percutaneous coronary intervention to 4 groups of risk of CIN (RC) according to MRS (low, medium, high, and very high risk). We evaluated CIN, death, and major cardiovascular and cerebrovascular events after 25 months' mean follow-up. At multivariable analysis, mortality in very high-risk group was more than 10-fold higher (hazard ratio [HR], 10.11; 95% confidence interval [CI], 4.83 to 21.1; P<0.001) when compared with the low-risk group and was also increased in the high-risk group (HR, 6.31; 95% CI, 3.28 to 12.14; P<0.001) and medium-risk group (HR, 3.18; 95% CI, 1.83 to 5.51; P<0.001). Similarly, an increasing effect was seen across MRS strata for major cardiovascular and cerebrovascular events both in the very high-risk group (HR, 3.79; 95% CI, 2.27 to 6.6.32; P<0.001), high-risk group (HR, 1.90; 95% CI, 1.31 to 2.75; P=0.001), and medium-risk group (HR, 1.42; 95% CI, 1.10 to 1.85; P=0.007). In addition, the HR for rehospitalization increased with the increasing RC groups (HR, 3.32; 95%CI, 1.96 to 5.63; P<0.001; HR, 3.11; 95% CI, 1.35 to 7.20; P=0.008; HR, 7.73; 95% CI, 2.97 to 20.10; P<0.001, respectively). The odds ratio for CIN was 2.84 (95% CI, 1.16 to 6.92; P=0.021) in the very high RC group, 1.33 (95% CI, 0.68 to 2.61; P=0.398) in the high RC group, and 1.10 (95% CI, 0.67 to 1.79; P=0.699) in the medium RC group, as compared with the lower one. CONCLUSIONS: The MRS may be applied in the primary angioplasty setting population and is able to predict CIN and to stratify patients for poor clinical outcomes both in the short- and long-term follow-up.
Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Kidney Diseases/etiology , Myocardial Infarction/diagnosis , Postoperative Complications , Aged , Aged, 80 and over , Contrast Media/administration & dosage , Electrocardiography , Female , Follow-Up Studies , Humans , Kidney Diseases/epidemiology , Kidney Diseases/mortality , Male , Middle Aged , Myocardial Infarction/epidemiology , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Predictive Value of Tests , Prognosis , Research Design , Risk Adjustment , Risk Assessment , Survival Analysis , Treatment OutcomeABSTRACT
An 85-year-old male patient, with long-standing hypertension, was admitted to our hospital for a late inferior myocardial infarction. An elective coronary angiogram was performed, but due to severe iliac artery tortuosity, thoracic aortic dilatation, high left coronary artery take-off, and separated origin of the left descending coronary artery and circumflex, selective cannulation with different catheter shapes was not possible. Thus, we decided to utilize a modified mother-child technique by cutting the first 10 cm from the hub of a conventional 7 F Judkins left 4 guiding catheter and inserting it into a 7 F valved sheath. Then, we introduced a conventional 6 F Amplatz Left 2 diagnostic catheter inside it. In this way, we were able to easily reach both separate ostia and to perform complete left coronary angiography. The technique we described herewith could represent a valid solution to allow utilization of standard coronary catheters with different shapes commercially available in cases of complex coronary artery origin.
Subject(s)
Cardiac Catheterization/methods , Coronary Angiography/methods , Coronary Vessels/pathology , Myocardial Infarction/diagnostic imaging , Aged, 80 and over , Cardiac Catheterization/instrumentation , Coronary Angiography/instrumentation , Equipment Design , Humans , MaleABSTRACT
We report a case of a middle-aged woman presenting with ST elevation myocardial infarction in early puerperium after Caesarean intervention secondary to left main coronary artery thrombosis, likely to be associated with thrombophilic state and concomitant use of oxytocin.
Subject(s)
Cesarean Section/adverse effects , Coronary Thrombosis/etiology , Myocardial Infarction/etiology , Oxytocics/adverse effects , Oxytocin/adverse effects , Thrombophilia/complications , Adult , Angioplasty, Balloon, Coronary , Blood Coagulation Tests , Coronary Angiography , Coronary Thrombosis/diagnosis , Coronary Thrombosis/therapy , DNA Mutational Analysis , Electrocardiography , Factor V/genetics , Female , Humans , Intra-Aortic Balloon Pumping , Mutation , Myocardial Infarction/diagnosis , Myocardial Infarction/therapy , Postpartum Period , Pregnancy , Thrombophilia/blood , Thrombophilia/diagnosis , Thrombophilia/genetics , Treatment OutcomeABSTRACT
BACKGROUND: Percutaneous coronary intervention (PCI) is a highly effective therapy for acute ST-elevation myocardial infarction. Adjunctive therapy with platelet glycoprotein (GP) IIb/IIIa inhibitor can result in increased vessel patency and improved outcomes in ST-elevation myocardial infarction patients undergoing PCI. The investigation of novel dosing and delivery strategies of this therapy may help to further improve outcomes. METHODS: IC-Clearly is a randomized, open-label, multicenter trial, with the purpose of evaluating the effectiveness of an intracoronary bolus dose of abciximab delivered using the ClearWay RX catheter vs. an intravenous bolus of abciximab for ST-elevation myocardial infarction with angiographically visible thrombus (thrombus grade >or=2). A total of 150 patients will be randomized 1: 1 to treatment of the culprit artery with intracoronary abciximab (75 patients) or intravenous abciximab (75 patients) in addition to a maintenance infusion regimen of abciximab administered intravenously for 12 h after PCI. The number of patients included in this study is based on the estimation of sample size needed to identify a statistically significant difference in the primary endpoints between the two groups. The primary endpoint chosen to evaluate this hypothesis is infarct size assessed by cardiac magnetic resonance. Clinical outcomes will be assessed for each patient through hospital discharge and at 30-day follow-up. CONCLUSION: The purpose of this study is to evaluate whether an intracoronary bolus of abciximab delivered with the ClearWay RX catheter prior to the 12 h post-PCI intravenous infusion regimen of abciximab will result in significant additional clot resolution in vivo and improved myocardial perfusion when compared with an intravenous bolus of abciximab on top of the 12 h post-PCI intravenous infusion regimen of abciximab as per standard practice. The primary endpoint chosen to evaluate this hypothesis is infarct size as assessed by cardiac magnetic resonance.
Subject(s)
Angioplasty, Balloon, Coronary , Antibodies, Monoclonal/administration & dosage , Coronary Thrombosis/therapy , Immunoglobulin Fab Fragments/administration & dosage , Myocardial Infarction/therapy , Platelet Aggregation Inhibitors/administration & dosage , Research Design , Abciximab , Cardiac Catheterization , Coronary Angiography , Coronary Thrombosis/diagnostic imaging , Coronary Thrombosis/drug therapy , Electrocardiography , Humans , Infusions, Intravenous , Injections, Intravenous , Italy , Magnetic Resonance Imaging , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/drug therapy , Myocardium/pathology , Sample Size , Time Factors , Treatment OutcomeABSTRACT
OBJECTIVES: This study analyzed the association of left ventricular end-systolic diameter (LVESD) with survival after diagnosis in organic mitral regurgitation (MR) due to flail leaflets. BACKGROUND: LVESD is a marker of left ventricular function in patients with organic MR but its association to survival after diagnosis is unknown. METHODS: The MIDA (Mitral Regurgitation International Database) registry is a multicenter registry of echocardiographically diagnosed organic MR due to flail leaflets. We enrolled 739 patients with MR due to flail leaflets (age 65 +/- 12 years; ejection fraction: 65 +/- 10%) in whom LVESD was measured (36 +/- 7 mm). RESULTS: Under conservative management, 10-year survival and survival free of cardiac death were higher with LVESD <40 mm versus > or =40 mm (64 +/- 5% vs. 48 +/- 10%; p < 0.001, and 73 +/- 5% vs. 63 +/- 10%; p = 0.001). LVESD > or =40 mm independently predicted overall mortality (hazard ratio [HR]: 1.95, 95% confidence interval [CI]: 1.01 to 3.83) and cardiac mortality (HR: 3.09, 95% CI: 1.35 to 7.09) under conservative management. Mortality risk increased linearly with LVESD >40 mm (HR: 1.15, 95% CI: 1.04 to 1.27 per 1-mm increment). During the entire follow-up (including post-surgical), LVESD > or =40 mm independently predicted overall mortality (HR: 1.86, 95% CI: 1.24 to 2.80) and cardiac mortality (HR: 2.14, 95% CI: 1.29 to 3.56), due to persistence of excess mortality in patients with LVESD > or =40 mm after surgery (HR: 1.86, 95% CI: 1.11 to 3.15 for overall death, and HR: 1.81, 95% CI: 1.05 to 3.54 for cardiac death). CONCLUSIONS: In MR due to flail leaflets, LVESD > or =40 mm is independently associated with increased mortality under medical management but also after mitral surgery. These findings support prompt surgical rescue in patients with LVESD > or =40 mm but also suggest that best preservation of survival is achieved in patients operated before LVESD reaches 40 mm.
Subject(s)
Heart Ventricles/diagnostic imaging , Mitral Valve Insufficiency/mortality , Myocardial Contraction/physiology , Ventricular Function, Left/physiology , Aged , Confidence Intervals , Echocardiography, Doppler , Europe/epidemiology , Female , Follow-Up Studies , Heart Ventricles/physiopathology , Humans , Male , Middle Aged , Mitral Valve Insufficiency/diagnostic imaging , Mitral Valve Insufficiency/physiopathology , Odds Ratio , Prognosis , Retrospective Studies , Survival Rate/trends , Systole , Time FactorsABSTRACT
Antiretroviral therapy has positively modified the natural history of HIV infection; but this treatment can induce metabolic abnormalities, including dyslipidemia, fat redistribution, high blood pressure, and insulin resistance. The metabolic syndrome, a clustering of the metabolic disorders, is frequently detected among HIV patients, especially those on antiretroviral treatment. All the arteries can modify their diameter in response to a chronic injury. This process, defined vascular remodeling, was demonstrated for the brachial artery. It is well known that the diameter of the brachial artery was correlated with the number of the elements of the metabolic syndrome and was associated with the severity of coronary artery disease. On this basis, we postulate that brachial arterial enlargement may be a process potentially correlated with the metabolic disorders induced by antiretroviral therapy. We tested this hypothesis in a large population of HIV-infected patients in which we measured brachial artery diameter, as an indicator of artery remodeling, by noninvasive, ultrasonographic technique. Our population consisted of 570 patients, with a mean age of 46.3 +/- 7.1 years. All the patients were chronically treated with highly active antiretroviral therapy. Brachial artery diameter was correlated with insulin resistance, evaluated by the homeostasis model assessment of insulin resistance index (r = 0.18, P < .0001). There was a significant linear increase in brachial artery diameter as the number of components of the metabolic syndrome increased: brachial artery diameter for those with 0, 1, 2, 3, or + characteristics was 39.3 +/- 7.2, 41.0 +/- 6.8, 42.0 +/- 7.3, and 43.8 +/- 7.9 mm, respectively (P < .001 for trend). In multivariable logistic regression analysis, brachial artery diameter was independently correlated with the presence of metabolic syndrome. Our results are in line with the hypothesis that, among HIV-infected patients chronically treated with antiretroviral therapy, those with a larger brachial artery diameter are at high risk for metabolic disorders, including a more severe insulin resistance and the presence of metabolic syndrome.
Subject(s)
Antiretroviral Therapy, Highly Active/adverse effects , Brachial Artery/pathology , HIV Infections/drug therapy , HIV Infections/metabolism , HIV/growth & development , Metabolic Syndrome/chemically induced , Adult , Aged , Brachial Artery/diagnostic imaging , Female , HIV Infections/pathology , HIV Infections/virology , Humans , Logistic Models , Male , Metabolic Syndrome/metabolism , Metabolic Syndrome/pathology , Metabolic Syndrome/virology , Middle Aged , Multivariate Analysis , Neovascularization, Pathologic/chemically induced , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Ultrasonography , Young AdultABSTRACT
We describe magnetic resonance (MR) aspect of cardiac glycogenesis in a 49-years old man, presented a progressively declining cardiac function and negative coronary angiography. Delayed enhancement MR confirmed non-ischemic pattern with unusual diffuse distribution of Gadolinium. Cardiac biopsy revealed a Glycogen Storage Disease, extralysosomial type. Cardiac MR with analysis of delayed enhancement distribution is an emerging tool that can discriminate between ischemic and non-ischemic diseases; however to identify the precise aetiology of a non-ischemic distribution, myocardial biopsy is still needed.
Subject(s)
Contrast Media , Glycogen Storage Disease/diagnosis , Image Enhancement/methods , Magnetic Resonance Imaging, Cine/methods , Myocardium/pathology , Ventricular Dysfunction, Left/diagnosis , Glycogen Storage Disease/complications , Humans , Male , Middle Aged , Ventricular Dysfunction, Left/etiologyABSTRACT
AIMS: To determine the frequency and predictors of left ventricular dilatation assessed by magnetic resonance imaging among patients with a first acute myocardial infarction treated with successful primary angioplasty and stent. METHODS AND RESULTS: Cine magnetic resonance imaging and late enhancement imaging were prospectively performed in 42 patients 1 month and more than 1 year after successful early reperfusion of a first acute ST elevation myocardial infarction (age 61 +/- 13 years, 76% men, 55% anterior myocardial infarction, and mean symptom-to-balloon time 199 +/- 130 min). Both at the 1-month and at the 15-month magnetic resonance imaging examinations, 57% of patients had left ventricular dilatation (end-systolic volume indexed > 36 ml/m2, values above the upper 95th percentile based on magnetic resonance imaging reference values for left ventricular size in normal participants). The most accurate predictor of left ventricular dilatation was maximum persisting single lead ST elevation 60 min after reperfusion (area under the curve 0.81, P = 0.001). Maximum single lead ST elevation was significantly and independently associated with larger end-systolic volume indexed (beta = 0.35, P = 0.040) after adjusting for muscle and brain isoenzyme of creatine kinase and echocardiographic wall motion score index. CONCLUSION: More than half of patients with a first acute myocardial infarction have left ventricular dilatation despite successful primary coronary angioplasty. Maximum persisting single lead ST elevation 60 min after mechanical reperfusion represents a simple tool for predicting left ventricular dilatation.
Subject(s)
Angioplasty, Balloon, Coronary , Heart Ventricles/pathology , Magnetic Resonance Imaging, Cine , Myocardial Infarction/therapy , Aged , Angioplasty, Balloon, Coronary/instrumentation , Dilatation, Pathologic , Female , Heart Ventricles/physiopathology , Humans , Male , Middle Aged , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Predictive Value of Tests , Prospective Studies , Severity of Illness Index , Stents , Stroke Volume , Time Factors , Treatment Outcome , Ventricular Function, LeftABSTRACT
OBJECTIVES: The purpose of this study was to assess incidence and predictors of events associated with nonsurgical and surgical management of severe mitral regurgitation (MR) in European institutions. BACKGROUND: The management of patients with MR remains disputed, warranting multicenter studies to define clinical outcome in routine clinical practice. METHODS: The MIDA (Mitral Regurgitation International DAtabase) is a registry created for multicenter study of MR with echocardiographically diagnosed flail leaflet as a model of pure, organic MR. Our cases were collected from 4 European centers. We enrolled 394 patients (age 64 +/- 11 years; 67% men; 64% in New York Heart Association functional class I to II; left ventricular ejection fraction 67 +/- 10%). RESULTS: During a median follow-up of 3.9 years, linearized event rates/year under nonsurgical management were 5.4% for atrial fibrillation (AF), 8.0% for heart failure (HF), and 2.6% for death. Mitral valve (MV) surgery was performed in 315 (80%) patients (repair in 250 of 315, 80%). Perioperative mortality, defined as death within 30 days from the operation, was 0.7% (n = 2). Surgery during follow-up was independently associated with reduced risk of death (adjusted hazard ratio [HR] 0.42, 95% confidence interval [CI] 0.21 to 0.84; p = 0.014). Benefit was largely driven by MV repair (adjusted HR vs. replacement 0.37, 95% CI 0.18 to 0.76; p = 0.007). In 102 patients strictly asymptomatic and with normal ventricular function, 5-year combined incidence of AF, HF, or cardiovascular death (CVD) was 42 +/- 8%. In these patients, surgery also reduced rates of CVD/HF (HR 0.26, 95% CI 0.08 to 0.89; p = 0.032). CONCLUSIONS: In this multicenter study, nonsurgical management of severe MR was associated with notable rates of adverse events. Surgery especially MV repair performed during follow-up was beneficial in reducing rates of cardiac events. These findings support surgical consideration in patients with MR due to flail leaflets for whom MV repair is feasible.
Subject(s)
Cardiac Surgical Procedures , Mitral Valve Insufficiency/therapy , Mitral Valve/surgery , Aged , Atrial Fibrillation/etiology , Atrial Fibrillation/prevention & control , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/mortality , Echocardiography, Doppler , Europe , Female , Heart Failure/etiology , Heart Failure/prevention & control , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Mitral Valve/diagnostic imaging , Mitral Valve/physiopathology , Mitral Valve Insufficiency/complications , Mitral Valve Insufficiency/mortality , Mitral Valve Insufficiency/physiopathology , Mitral Valve Insufficiency/surgery , Patient Selection , Proportional Hazards Models , Prospective Studies , Registries , Risk Assessment , Severity of Illness Index , Stroke Volume , Time Factors , Treatment Outcome , Ventricular Function, LeftABSTRACT
UNLABELLED: Information on the incidence of decompensation of chronic heart failure (CHF) in heart transplantation (HT) candidates eligible for prophylactic implantable cardioverter defibrillators (ICD) could provide insights into the influence of ICD on the timing for HT. METHODS: We investigated the prevalence of candidates satisfying SCD-HeFT and MADIT-II criteria for prophylactic ICD among patients (n = 317) with CHF referred to our tertiary center for HT. In addition to standard clinical and laboratory assessments, baseline evaluation included two-dimensional standard transthoracic echocardiogram and 12-lead electrocardiogram. RESULTS: At baseline, 19% of patients (n = 60) satisfied MADIT II criteria, and 58% (n = 185) fulfilled SCD-HeFT criteria. A total of 60% patients (n = 190) were eligible for prophylactic ICD implantation according to at least one set of criteria. Five-yr CHF decompensation-free survival was 68 +/- 4% in patients eligible for prophylactic ICD (p = 0.003), (RR 2.5, 95% CI 1.35-4.63). CONCLUSIONS: SCD-HeFT could imply a threefold rise in ICD eligibility in tertiary settings. As ICD-eligible patients would likely remain at high risk of progressive ventricular dysfunction, strict follow-up should be considered extremely important to allow a timely referral for HT.